A systematic review and meta-analysis of the IgA seroprevalence in COVID-19 patients: Is there a role for IgA in COVID-19 diagnosis or severity?

Rangel-Ramírez, Velia Verónica; Macías-Piña, Karen Alondra; Garrido, Roberto Raúl Servin; Alba-Aguayo, David R. de; Moreno-Fierros, Leticia; Rubio-Infante, Néstor

doi:10.1016/j.micres.2022.127105

Cited by 13 publications

(13 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, it appears that antibody tests are expected to have a beneficial role for detecting previous SARS-CoV-2 infection if used after two weeks since the onset of symptoms, while there are limited data beyond 35 days post-symptom period ( Deeks et al., 2020 ). According to an additional recent systematic review with meta-analysis, the detection of anti-SARS-CoV-2 IgM and IgG antibodies may assist in the early detection of SARS-CoV2 infection ( Fathi et al., 2021 ), while IgA production may predict more severe COVID19 ( Rangel-Ramirez et al., 2022 ). Furthermore, a previous study also showed a high prevalence of antiphospholipid antibodies (aPL) in patients with COVID19, with a recent meta-analysis and systematic review reporting that the most frequent type of aPL was lupus anticoagulant (LA) ( Taha and Samavati, 2021 ).…”

Section: Biomarkers Of Injury Of Organ Systems In Covid19mentioning

confidence: 99%

COVID19 biomarkers: What did we learn from systematic reviews?

Semiz

2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID19) pandemic continues to represent a substantial public health concern. It can rapidly progress to severe disease, with poor prognosis and a high mortality risk. An early diagnosis and specific prognostic tools can help healthcare providers to start interventions promptly, understand the likely prognosis and to identify and treat timely individuals likely to develop severe disease with enhanced mortality risk. Here we focused on an impressive set of systematic reviews and meta-analyses that were performed since the start of the COVID19 pandemic and summarized their results related to the levels of hematologic, inflammatory, immunologic biomarkers as well as markers of cardiac, respiratory, hepatic, gastrointestinal and renal systems and their association with the disease progression, severity and mortality. The evidence outlines the significance of specific biomarkers, including inflammatory and immunological parameters (C-reactive protein, procalcitonin, interleukin-6), hematological (lymphocytes count, neutrophil-to-lymphocyte ratio, D-dimer, ferritin, red blood cell distribution width), cardiac (troponin, CK-MB, myoglobin), liver (AST, ALT, total bilirubin, albumin) and lung injury (Krebs von den Lungen-6) that can be used as prognostic biomarkers to aid the identification of high-risk patients and the prediction of serious outcomes, including mortality, in COVID19. Thus, these parameters should be used as essential tools for an early risk stratification and adequate intervention in improving disease outcomes in COVID19 patients.

show abstract

Section: Biomarkers Of Injury Of Organ Systems In Covid19mentioning

confidence: 99%

COVID19 biomarkers: What did we learn from systematic reviews?

Semiz

2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…75 days after symptom onset). 39 Finally, a study that analysed 100 communities in Wuhan, China showed that the presence of specific IgA antibodies decreased rapidly over time, as for IgM, especially those infected but who were asymptomatic. 40 Our study will evaluate differences in seroprevalence between cohorts with different occupational exposures (HCWs, highly mobile workers, and university staff and students) believed to have differing a priori risks of exposure to SARS-CoV-2.…”

Section: Discussionmentioning

confidence: 99%

The dynamics and determinants of specific systemic and mucosal antibody responses to SARS-CoV-2 in three adult cohorts in the Ecuadorian Andes: a study protocol

et al. 2022

View full text Add to dashboard Cite

Introduction: There are limited longitudinal data on the systemic and mucosal antibody responses to SARS-CoV-2 from Latin America, a region severely affected by COVID-19, and where vaccine strategies have been implemented during the evolving pandemic. Objective: To evaluate determinants of seroprevalence and changes in levels of anti-SARS-CoV-2 antibodies longitudinally in adults with different levels of exposure to SARS-CoV-2 (defined a priori as low, medium, and high based on presumed occupational risk), in two Andean cities in Ecuador. Methods: Longitudinal cohort study of 1,000 adults aged 18 years and older with questionnaire data and sample collection done at 0, 3, 6, and 12 months during the period 2020-2023. Observations collected included WHO-ISARIC questionnaire and peripheral blood and saliva samples for measurement of IgG and IgA antibodies, respectively. Planned analyses are tailored to the longitudinal nature of the outcomes defined by participants’ antibody levels and aim at estimating their average trends with time since infection in each of the occupational groups, adjusted for demographics and calendar-time levels of SARS-CoV-2 infection in the general population. The latter reflect the impact of the national control measures such as vaccinations and movement restrictions. Importance: Understanding the duration and the dynamics of waning immunity to SARS-CoV-2, in the context of exposures to emerging virus variants and immunization, will inform the implementation of targeted public health strategies in the Latin American region. Ethics and Dissemination: This study will observe the bioethical principles of the Declaration of Helsinki. Informed written consent will be obtained. Samples from participants will be stored for up to three years after which they will be destroyed. The study protocol was approved by the Ecuadorian Ministry of Public Health Ethics Committee for COVID-19 Research. Antibody results will be provided to participants and participating institutions and to the national health authorities.

show abstract

“…32 Levels of IgA may also represent the degree of disease severity, as IgA production has been reported to be higher in severe patients compared to moderate or asymptomatic individuals. 33 IgA, secreted by local plasma cells against RBD on the virus's spike protein, potentially neutralizes SARS-CoV-2 before it binds to epithelial cells. 34 SIgA, the most abundant immunoglobulin secreted by mucosal surfaces, has a dimeric structure and comprises variable proportions of IgA1 and IgA2 subclasses.…”

Section: The Role Of Igamentioning

confidence: 99%

“…Surprisingly, salivary IgA is weakly matched with serum antibody levels which is partly attributable to the cross‐reactive IgA produced by exposure to viruses other than SARS‐CoV‐2 32 . Levels of IgA may also represent the degree of disease severity, as IgA production has been reported to be higher in severe patients compared to moderate or asymptomatic individuals 33 …”

Section: The Goodmentioning

confidence: 99%

A comprehensive review of oral microenvironment changes and orofacial adverse reactions after COVID‐19 vaccination: The good, the bad, and the ugly

Najary,

Vatankhah,

Khadivi

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

Background and AimsAnti‐severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccines have the potential to alter several biological systems concurrently with remolding the immune system, most of which are related to immunization, while some others are known as adverse effects. This review aims to explore the potential effects of vaccination on the oral microenvironment and classifies them as good, bad, or ugly, with a brief review of facial diseases following coronavirus disease 2019 (COVID‐19) vaccination.MethodsThis study was a comprehensive review conducted through searching related articles in Medline, Scopus, and Google Scholar databases.ResultsOn one side, the “Good” impacts of vaccination on the oro‐nasal mucosa are explained as if the mucosal immune responses followed by SARS‐CoV‐2 vaccines are enough to provide immunity. On the other side, the possible “Bad” and “Ugly” effects of the vaccine, which manifest as orofacial adverse events and autoimmune reactivations, respectively, should be noted. Exacerbation of pre‐existing autoimmune conditions such as lichen planus, pemphigus vulgaris, bullous pemphigoid, and Stevens‐Johnson syndrome have been reported.ConclusionCOVID‐19 vaccines could affect different biological systems alongside stimulating the immune system, and some of these effects are referred to as adverse effects. Nonetheless, these adverse effects are treatable, and healthcare professionals should not prevent patients from taking the first available vaccination.

show abstract

A systematic review and meta-analysis of the IgA seroprevalence in COVID-19 patients: Is there a role for IgA in COVID-19 diagnosis or severity?

Cited by 13 publications

References 54 publications

COVID19 biomarkers: What did we learn from systematic reviews?

COVID19 biomarkers: What did we learn from systematic reviews?

The dynamics and determinants of specific systemic and mucosal antibody responses to SARS-CoV-2 in three adult cohorts in the Ecuadorian Andes: a study protocol

A comprehensive review of oral microenvironment changes and orofacial adverse reactions after COVID‐19 vaccination: The good, the bad, and the ugly

Contact Info

Product

Resources

About